Alan Ashworth

5 ta ish

UCSF Helen Diller Family Comprehensive Cancer Center

1. PARP inhibitors: Synthetic lethality in the clinic

   Christopher J. Lord, Alan Ashworth

   Sharh maqolaOAOchiq kirish20173 iqtibos

   ABIABI:AkademIndex/2026.other.107390

2. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

   Hannah Farmer, Nuala McCabe, Christopher J. Lord +11

   Maqola20052 iqtibos

   ABIABI:AkademIndex/2026.other.107379

3. BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

   Yuqiao Shen, Farah Rehman, Ying Feng +7

   MaqolaOAOchiq kirish20132 iqtibos

   ABIABI:AkademIndex/2026.other.107384

4. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from <i>BRCA</i> Mutation Carriers

   Peter C.C. Fong, David S. Boss, Timothy A. Yap +12

   Maqola20092 iqtibos

   ABIABI:AkademIndex/2026.other.547124

5. Resistance to therapy caused by intragenic deletion in BRCA2

   Stacey L. Edwards, Rachel Brough, Christopher J. Lord +6

   Maqola20082 iqtibos

   ABIABI:AkademIndex/2026.other.677601